Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies - PubMed (original) (raw)
Review
. 2018 Mar;39(3):209-221.
doi: 10.1016/j.it.2017.11.006. Epub 2017 Dec 20.
Affiliations
- PMID: 29275092
- DOI: 10.1016/j.it.2017.11.006
Review
Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies
Shashi Gujar et al. Trends Immunol. 2018 Mar.
Abstract
Oncolytic viruses (OVs) represent a new class of cancer immunotherapeutics. Administration of OVs to cancer-bearing hosts induces two distinct immunities: antiviral and antitumor. While antitumor immunity is beneficial, antiviral immune responses are often considered detrimental for the efficacy of OV-based therapy. The existing dogma postulates that anti-OV immune responses restrict viral replication and spread, and thus reduce direct OV-mediated killing of cancer cells. Accordingly, a myriad of therapeutic strategies aimed at mitigating anti-OV immune responses is presently being tested. Here, we advocate that OV-induced antiviral immune responses hold intrinsic anticancer benefits and are essential for establishing clinically desired antitumor immunity. Thus, to achieve the optimal efficacy of OV-based cancer immunotherapies, strategic management of anti-OV immune responses is of critical importance.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Similar articles
- Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
Marchini A, Scott EM, Rommelaere J. Marchini A, et al. Viruses. 2016 Jan 6;8(1):9. doi: 10.3390/v8010009. Viruses. 2016. PMID: 26751469 Free PMC article. Review. - Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia.
Wang W, Liu S, Dai P, Yang N, Wang Y, Giese RA, Merghoub T, Wolchok J, Deng L. Wang W, et al. J Immunother Cancer. 2021 Sep;9(9):e002569. doi: 10.1136/jitc-2021-002569. J Immunother Cancer. 2021. PMID: 34593618 Free PMC article. - Arming oncolytic viruses to leverage antitumor immunity.
de Gruijl TD, Janssen AB, van Beusechem VW. de Gruijl TD, et al. Expert Opin Biol Ther. 2015 Jul;15(7):959-71. doi: 10.1517/14712598.2015.1044433. Epub 2015 May 10. Expert Opin Biol Ther. 2015. PMID: 25959450 Review. - The two-faces of NK cells in oncolytic virotherapy.
Marotel M, Hasim MS, Hagerman A, Ardolino M. Marotel M, et al. Cytokine Growth Factor Rev. 2020 Dec;56:59-68. doi: 10.1016/j.cytogfr.2020.06.005. Epub 2020 Jun 13. Cytokine Growth Factor Rev. 2020. PMID: 32586674 Review. - Fighting Cancer with Viruses: Oncolytic Virus Therapy in China.
Wei D, Xu J, Liu XY, Chen ZN, Bian H. Wei D, et al. Hum Gene Ther. 2018 Feb;29(2):151-159. doi: 10.1089/hum.2017.212. Hum Gene Ther. 2018. PMID: 29284308 Review.
Cited by
- A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors.
Leoni V, Vannini A, Gatta V, Rambaldi J, Sanapo M, Barboni C, Zaghini A, Nanni P, Lollini PL, Casiraghi C, Campadelli-Fiume G. Leoni V, et al. PLoS Pathog. 2018 Aug 6;14(8):e1007209. doi: 10.1371/journal.ppat.1007209. eCollection 2018 Aug. PLoS Pathog. 2018. PMID: 30080893 Free PMC article. - Involving stemness factors to improve CAR T-cell-based cancer immunotherapy.
Noraldeen SAM, Rasulova I, Lalitha R, Hussin F, Alsaab HO, Alawadi AH, Alsaalamy A, Sayyid NH, Alkhafaji AT, Mustafa YF, Shayan SK. Noraldeen SAM, et al. Med Oncol. 2023 Oct 1;40(11):313. doi: 10.1007/s12032-023-02191-7. Med Oncol. 2023. PMID: 37779152 Review. - Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapy.
Gujar S, Pol JG, Kumar V, Lizarralde-Guerrero M, Konda P, Kroemer G, Bell JC. Gujar S, et al. Nat Protoc. 2024 Sep;19(9):2540-2570. doi: 10.1038/s41596-024-00985-1. Epub 2024 May 20. Nat Protoc. 2024. PMID: 38769145 Review. - Challenges and Future Perspectives of Immunotherapy in Pancreatic Cancer.
Wandmacher AM, Letsch A, Sebens S. Wandmacher AM, et al. Cancers (Basel). 2021 Aug 23;13(16):4235. doi: 10.3390/cancers13164235. Cancers (Basel). 2021. PMID: 34439389 Free PMC article. Review. - The BRCA1 Pseudogene Negatively Regulates Antitumor Responses through Inhibition of Innate Immune Defense Mechanisms.
Han YJ, Zhang J, Lee JH, Mason JM, Karginova O, Yoshimatsu TF, Hao Q, Hurley I, Brunet LP, Prat A, Prasanth KV, Gack MU, Olopade OI. Han YJ, et al. Cancer Res. 2021 Mar 15;81(6):1540-1551. doi: 10.1158/0008-5472.CAN-20-1959. Epub 2021 Jan 20. Cancer Res. 2021. PMID: 33472891 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources